期刊文献+

多西紫杉醇联合希罗达治疗晚期乳腺癌33例临床观察 被引量:7

Clinical Observation of 33 Patients with Advanced Breast Cancer Treated with Docetaxel and Xeloda
下载PDF
导出
摘要 目的观察多西紫杉醇联合希罗达治疗晚期乳腺癌的疗效及毒副反应。方法多西紫杉醇75mg/m2,静滴1h,d1;希罗达2500mg/m2,口服,分早晚2次餐后服用,连用14d,21d为1周期,治疗2~4周期后评价疗效及毒副反应。结果33例均可评价疗效,完全缓解(CR)4例,部分缓解(PR)12例,稳定(SD)11例,进展(PD)6例,总有效率(CR+PR)48.5%。主要毒副反应为骨髓抑制、胃肠道反应、手足综合征。结论多西紫杉醇联合希罗达治疗晚期乳腺癌疗效较好,毒副反应轻,耐受性好,是晚期乳腺癌的有效治疗方案。 Objective To study the efficacy and toxicities of Decetaxel combined with Xeloda in treating patients with advanced breast cancer. Methods Docetaxel was given 70 mg/m^2 on day 1, and Xeloda was given 2 500 mg/m^2 twice a day for 14 days. The chemotherapy was repeated every 3 weeks, the efficacy and toxicities were reviewed after 2 to 4 cycles of chemotherapy. Results The 33 patients were evaluable for response. CR 4 cases, PR 12 cases, SD 11 cases, and PD 6 cases. The overall response rate was 48.5% (16/33). The main toxicities included myelosappression, gastrointestinal toxicities, hand-foot syndrome. Conclusion Docetaxed and Xeloda is effective in the treatment of patients with advanced breast cancer, the toxicity was acceptable and it may be a effective regimen.
出处 《肿瘤基础与临床》 2009年第1期38-39,共2页 journal of basic and clinical oncology
关键词 多西紫杉醇 希罗达 晚期乳腺癌 Docetaxel Xeloda advanced breast cancer
  • 相关文献

参考文献4

二级参考文献13

  • 1Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer:the TAX 326 study group [ J ]. J Clin Oncol, 2003,21 (16) :3007 -3008.
  • 2Kubota K,Watanabe K, Kunitoh H,et al. Phase Ⅲ randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage Ⅳ non-small-cell lung cancer: the Japanese Taxotere Lung Cancer study Group [ J ]. J Clin Oncol, 2004,22 (2) :254 -261.
  • 3Spielmann M, Llombart A, Zelek L, et al. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracyclineresistant advanced breast cancer [ J ]. Ann Oncol, 1999,10 ( 12 ) : 1457 - 1460.
  • 4Marty M,Cognetti F, Maraninchi D,et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer administered as first-line treatment : the M77001 study group [ J ]. J Clin Oncol,2005,23 ( 19 ) : 4265 - 4274.
  • 5Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage Ⅲ breast cancer [ J ]. Oncology, 1997,11 (8 Suppl 8) :15 - 18.
  • 6Blum JL,Buzdar AM,Dieras V,et al.A multicenter phase II trial of Xeloda (capecitabine) in taxane-refractory metastatic breast cancer[].Proceedings of the American Society of Clinical Oncology.1999
  • 7Ishikawa T,Sekiguchi F,Fukase Y,et al.Positive correlation between the efficacy of capecitabine and doxifluridine and the ration of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts[].Cancer Research.1998
  • 8Miwa M,Ura M,Nishida M,et al.Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[].European Journal of Cancer.1998
  • 9O′Reilly SM,Moiseyenko V,Talbot DC,et al.A randomized phase II study of Xeloda ( capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy[].Proceedings of the American Society of Clinical Oncology.1998
  • 10Wang ZW,Wong KK,Chew L,et al.Capecitabine as an oral chemotherapeutic agent in the treatment of refractory metastatic breast carcinoma (MBC)[].Proceedings of the American Society of Clinical Oncology.2000

共引文献73

同被引文献32

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部